Richard Labotka

3.7k total citations · 1 hit paper
104 papers, 2.6k citations indexed

About

Richard Labotka is a scholar working on Hematology, Molecular Biology and Genetics. According to data from OpenAlex, Richard Labotka has authored 104 papers receiving a total of 2.6k indexed citations (citations by other indexed papers that have themselves been cited), including 57 papers in Hematology, 50 papers in Molecular Biology and 36 papers in Genetics. Recurrent topics in Richard Labotka's work include Multiple Myeloma Research and Treatments (44 papers), Protein Degradation and Inhibitors (30 papers) and Hemoglobinopathies and Related Disorders (24 papers). Richard Labotka is often cited by papers focused on Multiple Myeloma Research and Treatments (44 papers), Protein Degradation and Inhibitors (30 papers) and Hemoglobinopathies and Related Disorders (24 papers). Richard Labotka collaborates with scholars based in United States, Greece and Spain. Richard Labotka's co-authors include Philip S. Low, Rama Kannan, Evelyn Brown, Cheryl A. Hillery, James G. Scott, Akira Omachi, Neeraj Gupta, William Galanter, George R. Honig and Karthik Venkatakrishnan and has published in prestigious journals such as Journal of the American Chemical Society, JAMA and Journal of Biological Chemistry.

In The Last Decade

Richard Labotka

101 papers receiving 2.5k citations

Hit Papers

Principles and Practice of Pediatric Oncology 1997 2026 2006 2016 1997 100 200 300 400
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Principles and Practice of Pediatric Oncology
    1997 490 citations Richard Labotka profile →

Peers

Richard Labotka
Michael L. Nieder United States
Gudmar Lönnerholm Sweden
Arlan J. Gottlieb United States
Michael Hayes United States
R. Donald Harvey United States
Jerome Seidenfeld United States
Yuan Li Shen China
Joseph M. Tuscano United States
Horst Schran United States
Brenda Gibson United Kingdom
Michael L. Nieder United States
Richard Labotka
Citations per year, relative to Richard Labotka Richard Labotka (= 1×) peers Michael L. Nieder

Countries citing papers authored by Richard Labotka

Since Specialization
Citations

This map shows the geographic impact of Richard Labotka's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Richard Labotka with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Richard Labotka more than expected).

Fields of papers citing papers by Richard Labotka

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Richard Labotka. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Richard Labotka. The network helps show where Richard Labotka may publish in the future.

Co-authorship network of co-authors of Richard Labotka

This figure shows the co-authorship network connecting the top 25 collaborators of Richard Labotka. A scholar is included among the top collaborators of Richard Labotka based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Richard Labotka. Richard Labotka is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Otani, Yuki, Richard Labotka, Mark Rogge, et al.. (2024). Modeling serum M‐protein response for early detection of biochemical relapse in myeloma patients treated with bortezomib, lenalidomide and dexamethasone. CPT Pharmacometrics & Systems Pharmacology. 13(12). 2124–2136.
2.
Delimpasi, Sosana, Meletios Α. Dimopoulos, Jan Štraub, et al.. (2024). Ixazomib plus daratumumab and dexamethasone: Final analysis of a phase 2 study among patients with relapsed/refractory multiple myeloma. American Journal of Hematology. 99(9). 1746–1756. 3 indexed citations
3.
Bringhen, Sara, Luděk Pour, Reuben Benjamin, et al.. (2023). Ixazomib Versus Placebo as Postinduction Maintenance Therapy in Newly Diagnosed Multiple Myeloma Patients: An Analysis by Age and Frailty Status of the TOURMALINE-MM4 Study. Clinical Lymphoma Myeloma & Leukemia. 23(7). 491–504. 2 indexed citations
4.
5.
Fu, Weijun, Juan Du, Lijuan Chen, et al.. (2023). Ixazomib Maintenance Therapy in Chinese Patients with Newly Diagnosed Multiple Myeloma Not Treated with Stem Cell Transplantation: A Single-Arm, Open-Label Study. Blood. 142(Supplement 1). 6735–6735. 1 indexed citations
6.
Paiva, Bruno, Irene Manrique, Meletios Α. Dimopoulos, et al.. (2022). MRD dynamics during maintenance for improved prognostication of 1280 patients with myeloma in the TOURMALINE-MM3 and -MM4 trials. Blood. 141(6). 579–591. 25 indexed citations
7.
Dimopoulos, Meletios Α., S. Vincent Rajkumar, Sagar Lonial, et al.. (2021). Interim Analyses of Overall Survival (OS) from the TOURMALINE MM3 & MM4 Studies of Ixazomib Maintenance Following Primary Therapy in Multiple Myeloma (MM). Blood. 138(Supplement 1). 1656–1656. 2 indexed citations
8.
Dimopoulos, Meletios Α., Ivan Špıčka, Hang Quach, et al.. (2020). Ixazomib as Postinduction Maintenance for Patients With Newly Diagnosed Multiple Myeloma Not Undergoing Autologous Stem Cell Transplantation: The Phase III TOURMALINE-MM4 Trial. Journal of Clinical Oncology. 38(34). 4030–4041. 53 indexed citations
9.
Kaiser, Martin, Meral Beksaç, Nina Gulbrandsen, et al.. (2020). Adverse event management in the TOURMALINE-MM3 study of post-transplant ixazomib maintenance in multiple myeloma. Annals of Hematology. 99(8). 1793–1804. 6 indexed citations
10.
Dimopoulos, Meletios Α., Sebastian Grosicki, W Wiktor-Jędrzejczak, et al.. (2018). All-oral ixazomib, cyclophosphamide, and dexamethasone for transplant-ineligible patients with newly diagnosed multiple myeloma. European Journal of Cancer. 106. 89–98. 27 indexed citations
11.
Gupta, Neeraj, Michael J. Hanley, Cindy Q. Xia, et al.. (2018). Clinical Pharmacology of Ixazomib: The First Oral Proteasome Inhibitor. Clinical Pharmacokinetics. 58(4). 431–449. 52 indexed citations
12.
Kutlar, Abdullah, Kenneth I. Ataga, Marvin Reid, et al.. (2012). A phase 1/2 trial of HQK‐1001, an oral fetal globin inducer, in sickle cell disease. American Journal of Hematology. 87(11). 1017–1021. 24 indexed citations
13.
Wilkie, Diana J., et al.. (2010). Sickle Cell Disease: An Opportunity for Palliative Care Across the Life Span. Nursing Clinics of North America. 45(3). 375–397. 34 indexed citations
14.
15.
Labotka, Richard, et al.. (1999). Acetylation of Human Hemoglobin by Methyl Acetylphosphate. Journal of Biological Chemistry. 274(38). 26629–26632. 8 indexed citations
16.
Schneider, Arthur S., Beryl Westwood, Michel Cohen‐Solal, et al.. (1996). The 1591C Mutation in Triosephosphate Isomerase (TPI) Deficiency. Tightly Linked Polymorphisms and a Common Haplotype in All Known Families. Blood Cells Molecules and Diseases. 22(2). 115–125. 13 indexed citations
17.
Schneider, Arthur S., Beryl Westwood, Josef T. Prchal, et al.. (1995). Triosephosphate isomerase deficiency: Repetitive occurrence of point mutation in amino acid 104 in multiple apparently unrelated families. American Journal of Hematology. 50(4). 263–268. 20 indexed citations
18.
19.
Ramasamy, Ravichandran, Duarte Mota de Freitas, Vinod Bansal, Elizabeth Dorus, & Richard Labotka. (1990). Nuclear magnetic resonance studies of lithium transport in erythrocyte suspensions of hypertensives. Clinica Chimica Acta. 188(2). 169–176. 7 indexed citations
20.
Labotka, Richard, et al.. (1990). A dialysis cell for nuclear magnetic resonance spectroscopic measurement of protein-small molecule binding. Analytical Biochemistry. 191(2). 376–383. 5 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Michael L. Nieder Breakdown of academic impact, for papers by Gudmar Lönnerholm Breakdown of academic impact, for papers by Arlan J. Gottlieb Breakdown of academic impact, for papers by Michael Hayes Breakdown of academic impact, for papers by R. Donald Harvey Breakdown of academic impact, for papers by Jerome Seidenfeld Breakdown of academic impact, for papers by Yuan Li Shen Breakdown of academic impact, for papers by Joseph M. Tuscano Breakdown of academic impact, for papers by Horst Schran Breakdown of academic impact, for papers by Brenda Gibson
Rankless by CCL
2026